Tubular cell-specific RXRα knockout mice will help to answer these questions in future studies; meanwhile, the present study suggests that a chromatin-based mechanism could be targeted as a therapeutic regimen and for drug repurposing in AKI treatment. This evidence concerns the gene RXRA and acute kidney injury.